Somewhat Favorable Press Coverage Somewhat Unlikely to Impact NeoGenomics (NEO) Stock Price
News stories about NeoGenomics (NASDAQ:NEO) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. NeoGenomics earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.4982895629405 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- (Motorcycling) Marquez on pole for Czech GP (wpsuperfanboy.com)
- NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Is Momentum Building For Neogenomics Inc (NEO)? – Evergreen Caller (evergreencaller.com)
- Neogenomics Inc (NEO) AroonUp Indicator Showing Strength – Evergreen Caller (evergreencaller.com)
- Financial Review: NeoGenomics (NEO) & RadNet (RDNT) (americanbankingnews.com)
NeoGenomics (NASDAQ:NEO) traded up 0.76% on Monday, reaching $9.32. The company’s stock had a trading volume of 142,654 shares. NeoGenomics has a one year low of $6.90 and a one year high of $9.93. The stock’s market cap is $738.49 million. The stock has a 50-day moving average of $8.89 and a 200-day moving average of $8.16.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $66.09 million during the quarter, compared to analysts’ expectations of $62.95 million. NeoGenomics had a positive return on equity of 6.02% and a negative net margin of 2.81%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.04 earnings per share. On average, analysts predict that NeoGenomics will post $0.18 EPS for the current fiscal year.
A number of research analysts have weighed in on NEO shares. BidaskClub lowered NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Saturday, July 29th. Cantor Fitzgerald set a $11.00 target price on NeoGenomics and gave the company a “buy” rating in a report on Saturday, May 27th. ValuEngine raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $11.00 target price on shares of NeoGenomics in a report on Sunday, May 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. NeoGenomics has a consensus rating of “Buy” and a consensus price target of $10.40.
In other NeoGenomics news, VP Jennifer Balliet sold 10,723 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $8.49, for a total value of $91,038.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alison L. Hannah purchased 20,000 shares of NeoGenomics stock in a transaction on Thursday, July 27th. The stock was bought at an average price of $9.19 per share, with a total value of $183,800.00. Following the transaction, the director now owns 38,782 shares of the company’s stock, valued at $356,406.58. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 84,890 shares of company stock valued at $665,707. Company insiders own 12.20% of the company’s stock.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.